Suchergebnisse - "Tabernero, J"

PubPharm (10)

1

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

enthalten in: ESMO open | 2022

von Borazanci, E. | Schram, A. | Garralda, E. | +20

2

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Tabernero, J. | Hozak, R. | Yoshino, T. | +15

CommentIn: Ann Oncol. 2018 Mar 1;29(3):527-529. - PMID 29360914

3

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Arnold, D. | Fuchs, C. | Tabernero, J. | +16

4

Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Obermannová, R. | Van Cutsem, E. | Yoshino, T. | +14

5

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

enthalten in: British journal of cancer | 2016

von Elez, E. | Hendlisz, A. | Delaunoit, T. | +6

6

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Cohn, A. | Tabernero, J. | Maurel, J. | +15

7

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer : a multicenter, retrospective analysis

enthalten in: Medical oncology (Northwood, London, England) | 2011

von Bouchahda, M. | Macarulla, T. | Liedo, G. | +13

8

Cetuximab administered once every second week to patients with metastatic colorectal cancer : a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2010

von Tabernero, J. | Ciardiello, F. | Rivera, F. | +10

9

Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer

enthalten in: Critical reviews in oncology/hematology | 2008

von Bouchahda, M. | Macarulla, T. | Spano, J. | +9

10

Monoclonal antibodies in the treatment of advanced colorectal cancer

enthalten in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2007

von Capdevila, J. | Saura, C. | Macarulla, T. | +3

1
[1]